cd8 t cell depletion experiment  (Bio X Cell)

Journal: Nature Communications

Article Title: Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer

doi: 10.1038/s41467-026-69311-5

Figure Lengend Snippet: A The expression of neutrophils and CD8 + T cells in low- and high-glycolysis clusters, divided by ssGSEA score of glycolysis-related genes, in TCGA and CPTAC PAAD database. Data are presented as box plots showing the median (center line), the first and third quartiles (box bounds), and the whiskers extend to 1.5 times the interquartile range from the box. B The correlation of glycolysis level and neutrophils or CD8 + T cells expression in TCGA ( n = 179 patients) and CPTAC ( n = 140 patients) PAAD database. C Kaplan–Meier plots representing survival probabilities in TCGA-PAAD patients according to the relative level of glycolysis-related or neutrophil-related gene expression. D The diagram illustrating the targets of 2DG and shRNA in the glycolysis process. E CyTOF analysis of tumor-infiltrating immunocytes in subcutaneous tumor models with or without 2DG treatment: tSNE plots showing 12 meta-clusters based on the expression of 41 markers for the immunocytes. F Bar chart of the frequencies of the immune cell subsets in two experimental groups. G A schematic diagram showing the orthotopic PDAC model ( n = 6 mice per group in one experiment) with or without 2DG treatment. H , I Image and weights of the orthotopic tumors in the experimental groups from ( G ) at the end of the experiments. ( n = 6 mice per group). ( J – M ) Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). N A schematic diagram showing the orthotopic tumor model in C57BL/6 J mice ( n = 6 mice per group in one experiment) treated with or without anti-Ly6G/anti-CD8 antibody. O , P Image and weights of the orthotopic tumors in the experimental groups from ( N ) at the end of the experiments ( n = 6 mice per group). Q – S Tumor-infiltrating neutrophils, CD8 + T cells, and GZMB + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry: Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). T , U Representative luminescence images of the mouse model in ( N ) and statistical analysis of the total flux ( n = 6 mice per group). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( A, I–M, P–S, and U ), two-tailed Pearson’s correlation analysis ( B ), and log-rank test ( C ). Source data are provided as a Source Data file.

Article Snippet: After 11 consecutive days of antibody administration, the mice were euthanized, the peripheral blood was harvested for flow cytometry analysis to assess the efficiency of neutrophil depletion; (3) For CD8 + T cells depletion, mice received an intraperitoneal injection of anti-IgG2a or anti-CD8 antibody (Selleck, #A2102) treatment (0.2 mg/mouse, i.p.) 2 days before implantation.

Techniques: Expressing, Gene Expression, shRNA, Isolation, Flow Cytometry, Two Tailed Test

Journal: Nature Communications

Article Title: Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer

doi: 10.1038/s41467-026-69311-5

Figure Lengend Snippet: A The flowchart illustrates that RNA sequencing was conducted using two PDAC cell lines with or without 2DG treatment. Subsequently, the intersection of detected genes within the chemokine family in both cell lines is identified, and a heatmap is generated to display the log 2 fold change (2DG versus vehicle) of these genes. B , C Relative mRNA levels of Cxcl1 in PDAC cell lines following glycolysis inhibition, either by using 2DG or silencing LDH, were analyzed by qRT-PCR ( n = 3 independent experiments). D , E Relative protein levels of CXCL1 in PDAC cell lines following glycolysis inhibition, either by using 2DG or silencing LDH, were determined using ELISA assay ( n = 3 independent experiments). F Representative IHC images of subcutaneous tumors ( n = 6 mice for 2DG treatment, n = 5 mice for shLDH/shNTC groups) stained by CXCL1 antibody (scale bars = 100 μm). G Relative serum CXCL1 levels in mice treated with or without 2DG were measured by ELISA ( n = 6 mice per group). H Relative serum CXCL1 levels in healthy donors and PDAC patients were measured by ELISA (22 healthy samples and 27 PDAC samples). I Schematic diagram showing the in vitro migration assay: human/mouse neutrophils were co-incubated with the culture medium supernatant from PDAC cells treated with 2DG or LDH-knockdown. J Neutrophils were co-cultured with CD8 + T cells in different proportions, and the proliferation of CD8 + T cells was detected with the CFSE assay ( n = 6 biologically independent samples). K The migratory activity of neutrophils co-incubated with the culture medium supernatant from PDAC cells treated with shLDH and recombinant CXCL1 was analyzed by counting the penetrated cell numbers ( n = 3 biologically independent samples). L The neutrophils were treated with SX-682 or Navarixin for 1.5 h in advance, and the migratory activity of neutrophils co-incubated with the culture medium supernatant from PDAC cell lines treated with shLDH was analyzed by counting the penetrated cell numbers ( n = 3 biologically independent samples). M Representative luminescence images of the orthotopic tumor in mice and statistical analysis of MFI ( n = 5 mice per group). N Tumor-infiltrating neutrophils isolated from the orthotopic tumors were analyzed using flow cytometry ( n = 5 mice per group). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test. Source data are provided as a Source Data file.

Article Snippet: After 11 consecutive days of antibody administration, the mice were euthanized, the peripheral blood was harvested for flow cytometry analysis to assess the efficiency of neutrophil depletion; (3) For CD8 + T cells depletion, mice received an intraperitoneal injection of anti-IgG2a or anti-CD8 antibody (Selleck, #A2102) treatment (0.2 mg/mouse, i.p.) 2 days before implantation.

Techniques: RNA Sequencing, Generated, Inhibition, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Staining, In Vitro, Migration, Incubation, Knockdown, Cell Culture, CFSE Assay, Activity Assay, Recombinant, Isolation, Flow Cytometry, Two Tailed Test

Journal: Nature Communications

Article Title: Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer

doi: 10.1038/s41467-026-69311-5

Figure Lengend Snippet: A Molecular docking simulated the binding affinities of PCAF for acetyl-CoA and lactyl-CoA. B Co-IP was performed to confirm the interaction between H3K18la and PCAF in PANC1 and KPC cells. PCAF and H3K18la were detected on the same gel. C, D Western blot analysis demonstrates the level of H3K18la in PDAC cells with or without the treatment of PCAF inhibitors (bromosporine or Embelin). Histone H3 and H3K18la blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. E Western blot analysis demonstrates the level of H3K18la in PDAC cells following the knockdown of Pcaf . Histone H3, PCAF, β-actin and H3K18la blots are from parallel-processed separate gels with samples from the same experiment. F Western blots of in vitro histone acetylation or lactylation assay, the samples as indicated. Blots are from parallel-processed separate gels with samples from the same experiment. G , H Relative Cxcl1 RNA and protein levels with the vehicle or bromosporine treatment were analyzed by qRT-PCR and ELISA ( n = 3 independent experiments), respectively. I Relative Cxcl1 RNA levels after Pcaf knockdown were analyzed by qRT-PCR ( n = 3 independent experiments). J A schematic diagram showing the orthotopic tumor construction in C57BL/6 J mice ( n = 5 mice per group in one experiment, 2 × 10 6 KPC-luc cells per mouse) with or without bromosporine treatment. K , L Image and weights of the orthotopic tumors in the experimental groups from ( J ) at the end of the experiments ( n = 5 mice per group). M Lactylation levels of H3K18 and PanK in orthotopic tumors with or without bromosporine treatment were detected by western blot ( n = 4 biologically independent samples per group). Histone H3, H3K18la, and PanKla blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. N Serum CXCL1 levels in mice with or without bromosporine treatment were measured by ELISA ( n = 5 mice per group). O – R Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells isolated from the orthotopic tumors were analyzed using flow cytometry. Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 5 mice per group). S The migratory abilities of neutrophils co-incubated with the culture medium supernatant from shNTC/ Pcaf PDAC cells treated with recombinant CXCL1 were analyzed by counting the penetrated cell numbers ( n = 3 biologically independent samples). T Representative IHC images stained by CXCL1 or H3K18la antibody (scale bar = 100 μm, left panel), correlation analysis of H-scores of CXCL1 and H3K18la in PDAC samples ( n = 21 patients, right panel). Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( G – I , L , and N – S ) and two-tailed Pearson’s correlation analysis ( T ). Unless otherwise indicated, all western blots had three independent experimental repetitions with consistent results. Source data are provided as a Source Data file.

Article Snippet: After 11 consecutive days of antibody administration, the mice were euthanized, the peripheral blood was harvested for flow cytometry analysis to assess the efficiency of neutrophil depletion; (3) For CD8 + T cells depletion, mice received an intraperitoneal injection of anti-IgG2a or anti-CD8 antibody (Selleck, #A2102) treatment (0.2 mg/mouse, i.p.) 2 days before implantation.

Techniques: Binding Assay, Co-Immunoprecipitation Assay, Western Blot, Knockdown, In Vitro, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Isolation, Flow Cytometry, Incubation, Recombinant, Staining, Two Tailed Test

Journal: Nature Communications

Article Title: Histone lactylation increases CXCL1 expression for neutrophil infiltration and immune escape in pancreatic cancer

doi: 10.1038/s41467-026-69311-5

Figure Lengend Snippet: A A schematic diagram showing the subcutaneous tumor model ( n = 6 mice per group in one experiment, 6 × 10 6 PANC02 cells per mouse) treated with bromosporine and anti-PD-1 antibody. B. The tumor volume growth curves of subcutaneous tumors from ( A ). C , D Image and weights of the subcutaneous tumors at the end point of experiments ( n = 6 mice per group). E The statistical analysis of the cell ratio of tumor-infiltrating neutrophils and CD8 + T cells isolated from subcutaneous tumors ( n = 3 mice per group). F Western blot analysis demonstrates H3K18la levels in the subcutaneous tumors ( n = 3 biologically independent samples per group) from ( A ). Histone H3 and H3K18la blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. G Relative serum CXCL1 levels in mice treated with or without bromosporine/anti-PD-1 antibody were measured by ELISA ( n = 6 mice per group). H A schematic diagram showing the combinational treatment schedule for the orthotopic KPC-luc tumor model ( n = 21 mice per group in one experiment, 2 × 10 6 KPC-luc cells per mouse). I , J Image and weights of the orthotopic tumors at the end point of experiments ( n = 6 mice per group). K – N Tumor-infiltrating neutrophils, CD8 + T cells, GZMB + CD8 + T cells, and PD-1 + CD8 + T cells were analyzed using flow cytometry. Representative graphs of flow cytometry (left panel) and statistical analysis of the cell ratio (right panel) ( n = 6 mice per group). O Western blot analysis showing the H3K18la levels in the orthotopic tumors ( n = 3 biologically independent samples per group) from ( H ). Histone H3 and H3K18la blots are from parallel-processed separate gels (size conflict) with samples from the same experiment. P Representative luminescence images and Quantification of radiance intensity of the mouse model in ( H ). Q Survival probability of mice with orthotopically transplanted PDAC ( n = 15 mice per group). R A working model displaying the signaling pathway through which the aerobic glycolysis-mediated Lactate-PCAF-H3K18la-CXCL1 axis modulates the tumor microenvironment in pancreatic cancer, and the scientific basis for the development of a novel therapeutic strategy for PDAC. Data represent mean ± SEM. Statistical analysis was conducted using the two-tailed unpaired Student’s t test ( B , D , E , G , J – N , P ) and the log-rank test ( Q ). Source data are provided as a Source Data file.

Article Snippet: After 11 consecutive days of antibody administration, the mice were euthanized, the peripheral blood was harvested for flow cytometry analysis to assess the efficiency of neutrophil depletion; (3) For CD8 + T cells depletion, mice received an intraperitoneal injection of anti-IgG2a or anti-CD8 antibody (Selleck, #A2102) treatment (0.2 mg/mouse, i.p.) 2 days before implantation.

Techniques: Isolation, Western Blot, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Two Tailed Test

Journal: bioRxiv

Article Title: The innate cytokine IL-18 inhibits CNS autoimmunity through preferential activation of protective CD8 T-cells

doi: 10.64898/2026.01.26.701759

Figure Lengend Snippet: (A) Representative histograms of IL-18R1 expression on NK cells, CD44 + CD8 T-cells, and CD44 + CD4 T-cells from day 20 dLN. (B) Mean EAE clinical score of WT (n=13), Il18tg (n=14), and Il18tg;Il18r1 ΔT (n=12) mice. (C) Flow cytometric quantification of splenic leukocytes at days 20-21. (D) Quantitation of individual cytokine production by splenic CD4 T-cells assessed by ICS following PMA/Iono stimulation. (E) Percent and absolute number of T-cells and (F) FOXP3 + CD4T reg in spinal cords by flow cytometry. (G) Quantitation of individual cytokine production by spinal cord CD4 T-cells by ICS following PMA/Iono stimulation. (A) Representative of 3 experiments. Data pooled from (C-G) 2 or (B) 3 experiments. Error bars = SEM. Statistical analysis: (B) Kruskal-Wallis of AUC with Dunns post-test of pairwise comparisons, (C, F) one-way ANOVA with Dunnett’s post-test of pairwise comparisons to Il18tg , (D, E, G) 2way ANOVA with Dunnett’s post-test of pairwise comparisons to Il18tg . Only p adj <0.05 is shown. *p< 0.05, **p<0.01, ***p<0.001.

Article Snippet: Anti-CD8a depleting antibody (200ug, YTS169.4, BioXcell) on days −3, 0, 3, and 6.

Techniques: Expressing, Quantitation Assay, Flow Cytometry

Journal: bioRxiv

Article Title: The innate cytokine IL-18 inhibits CNS autoimmunity through preferential activation of protective CD8 T-cells

doi: 10.64898/2026.01.26.701759

Figure Lengend Snippet: Expression of (A) effector markers and (B) putative suppressive markers on splenic CD8 T-cells from WT and Il18bp KO mice at day 12. (C) IFNg production by day 12 splenic CD8 T-cells following PMA/Ionomycin or MOG 35-55 stimulation by ICS. (D) Representative flow plots of day 18 spinal cord T-cells. (E) Quantification of spinal cord CD4 and CD8 T-cells and the corresponding CD4:CD8 ratio. (F) Expression of key effector surface markers on spinal cord CD8 T-cells. (G) Representative flow plots and quantification of dual-expressing CD38 + PD-1 + CD8 T-cells. (H) Mean EAE clinical score of WT and Il18bp KO mice receiving isotype (n=5) or CD8-depleting antibodies (n=7; 200ug, i.p., days −3, 0, 3, and 6) ( I) Representative plots of CD4 versus CD8 expression on splenic T-cells at day 25. (A,B, E, G, H) Data pooled from 2 experiments. (C,F) Data representative of 2-3 experiments. Error bars = SEM. Statistical analysis: (A-C, E-G) unpaired t-tests, p-value with Holm-Sidak correction with multiple comparisons, (H) Kruskal-Wallis of AUC with Dunn’s post-test of pairwise comparisons of Il18bp KO isotype vs anti-CD8. Only p adj <0.05 is shown. *p< 0.05, **p<0.01, ****p<0.0001.

Article Snippet: Anti-CD8a depleting antibody (200ug, YTS169.4, BioXcell) on days −3, 0, 3, and 6.

Techniques: Expressing

Journal: bioRxiv

Article Title: The innate cytokine IL-18 inhibits CNS autoimmunity through preferential activation of protective CD8 T-cells

doi: 10.64898/2026.01.26.701759

Figure Lengend Snippet: (A) Mean clinical score of WT (n=12), Il18tg (n=10), and Il18tg Il18r1 ΔCD8 (n=9) mice treated with tamoxifen at days 4 and 6. (B) IL-18R1 expression on activated (CD44 + ) CD4Tconv and CD8 T-cells. (C) Expression of CD44 on CD4T conv in dLN. ( D) Quantification of T-cell subsets in day 23 spinal cords as percent of CD45, CD4:CD8 ratio, and absolute number. ( E) CD8 T-cell activation (defined as CD62L-) and expression of putative CD8Tsupp markers in dLN. (F ) CD8 T-cell expression of putative CD8Tsupp markers and ( G) quantification of FOXP3+CD4T reg in day 23 spinal cords. (H) Serum IFNg concentration of the indicated genotypes at day 23. (A) Data pooled from 2 experiments and representative of 3 total. (B-H) Data representative of 3 experiments. Error bars = SEM. Statistical analysis: (A) Kruskal-Wallis of AUC with Dunn’s post-test of pairwise comparisons, (B-H) one-way ANOVA with Dunnett’s post-test of pairwise comparisons, (D, E, G) 2way ANOVA with Dunnett’s post-test of pairwise comparisons. All comparisons made to Il18tg control. Only p adj <0.05 is shown. *p< 0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Article Snippet: Anti-CD8a depleting antibody (200ug, YTS169.4, BioXcell) on days −3, 0, 3, and 6.

Techniques: Expressing, Activation Assay, Concentration Assay, Control

Journal: bioRxiv

Article Title: The innate cytokine IL-18 inhibits CNS autoimmunity through preferential activation of protective CD8 T-cells

doi: 10.64898/2026.01.26.701759

Figure Lengend Snippet: (A) Mean EAE clinical score of WT mice treated with PBS (n=19) or DR-18 (2ug, Subq, q3d; n=16) from days 0 to 15. (B) Mean EAE clinical score of WT and E8i cre ;Il18r1 fl/fl mice treated with PBS or DR-18 (n=9; 2ug, treated every 3 days from 0 to 30). (C) Mean EAE clinical score of WT mice treated with PBS or DR-18 at various timepoints indicated below the graph (treatment every 3 days from 0 to 15, colored dot corresponds to DR-18 treatment while no dot indicates PBS; n=10 for all groups). (D-I) 2.5×10 5 splenic CD4 T-cells from naïve 2D2 mice were transferred to WT and Il18bp KO mice on day −1. Half of the WT mice were randomized to receive DR-18 (n=8 per timepoint) or PBS (n=8 per timepoint) on days 9, 12, & 15. (D) Quantification of transferred splenic 2D2 T-cells, (E) CD49d expression on day 12 splenic 2D2, (F) and CD4T conv and 2D2 in day 18 spinal cord. (G) Absolute number of splenic FOXP3+ CD4T reg and CD8T eff (CD44 + CD62L − ) cells over time. (H) Expression of various surface markers and (I) CD38/PD-1 co-expression on splenic CD8 T-cells at day 12 and 18 from WT mice treated with PBS and DR-18. Data pooled from (B-I) 2 or (A) 3 experiments. Error bars = SEM except for box and whisker plot. Statistical analysis: (A) Mann-Whitney of AUC, (B,C) Kruskal-Wallis of AUC with Dunn’s post-test of pairwise comparisons to DR-18 (B) or PBS control (C), (D, G) unpaired t-tests of WT vs WT+DR-18 on days 12 and 18 only with Holm-Sidak correction of p-value, (E) one-way ANOVA with Dunnett’s post-test of pairwise comparisons (H,I) unpaired t-tests with Holm-Sidak correction of p-value. Only p adj <0.05 is shown. *p< 0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Article Snippet: Anti-CD8a depleting antibody (200ug, YTS169.4, BioXcell) on days −3, 0, 3, and 6.

Techniques: Expressing, Whisker Assay, MANN-WHITNEY, Control

Journal: Cancer immunology research

Article Title: RAS(ON) multi-selective inhibition drives antitumor immunity in preclinical models of NRAS -mutant melanoma

doi: 10.1158/2326-6066.CIR-25-0744

Figure Lengend Snippet: (A) Flow cytometry analysis of melanoma antigen panel for MHC-I, MHC-II and PD-L1 in control, responder, and treatment escape groups. Tumor cells were normalized to SOX10 + cells, n=3/group. (B) Immunohistochemistry (IHC) staining and quantification of MHC-I and PD-L1 expression in control, responder, and treatment escape groups, n=3/group. H-score was used to access MHC-I expression and the percentage of positive cells for PD-L1. (C) Flow cytometry analysis of T cell panel (number of infiltrated CD4 + and CD8 + T cells, activated CD4 + /CD69 + and CD8 + /CD69 + T cells, and memory CD44 + /CD62L − /CD4 + and CD44 + /CD62L − /CD8 + T cells) of control, responder, and treatment escape groups. Cells were normalized to the total number of live cells. (D) Flow cytometry analysis of Foxp3 + CD4 + T cells (Tregs) in control, responder, and treatment escape groups. Tregs were normalized to the total number of CD4 + cells. (E) Immunohistochemistry staining and quantification of CD8, CD69 and PD-1 expression in control, responder, and treatment escape groups. n=3/group. H-score was used to access CD8 and CD69 expressions and the percentage of positive cells for PD1, according to the best fit suggested by the software. (F) Flow cytometry analysis of exhaustion markers (PD-1, TIM-3, LAG-3 and CTLA-4) in control, responder, and treatment escape groups. T cells were normalized to the total number of live cells. Scale bar = 200 μm (G) Multiplex immunofluorescence (IF) staining of control, responder, and treatment escape tumors for DAPI, CD4, CD8, CD11b, CD11c, Ly6G, Ly6C, CD34 and SOX10 expression (H) Scoring of the multiplex IF images of the whole slides. (I) Degrees of clustering of CD4 + or CD8 + T cells versus M-MDSCs (CD11b + Ly6C + Ly6G − ) and PMN-MDSCs (CD11b + Ly6C − Ly6G + ) of control, responder, and treatment escape groups, n=3/group. Cells were normalized by the number of total cells. The graphs are represented as average ± SEM. One-way ANOVA was performed followed by Tukey’s multiple comparisons test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ns: non-significant; C: control (not treated cells); R: responder; TE: treatment escape.

Article Snippet: For CD4 + and CD8 + T-cell depletion, specific antibodies (anti-CD4, clone YTS191; cat. #BE0003–1; BioXCell, RRID:AB_1107636 and anti-CD8a, clone YTS169.4, cat. #BE0117, BioXCell, RRID:AB_10950145) were used.

Techniques: Flow Cytometry, Control, Immunohistochemistry, Expressing, Staining, Software, Multiplex Assay, Immunofluorescence

Journal: Cancer immunology research

Article Title: RAS(ON) multi-selective inhibition drives antitumor immunity in preclinical models of NRAS -mutant melanoma

doi: 10.1158/2326-6066.CIR-25-0744

Figure Lengend Snippet: (A-B) Tumor growth and survival curves following pre-treatment with IgG control (n=5) or anti-CD4 + anti-CD8a +/− RMC-7977 (all n=15). Vehicle or RMC-7977 treatment was initiated when tumors reached around 100mm 3 . For T cell depletion, mice were treated 3 days before the injection of the tumor with the Anti-CD4 and Anti-CD8a antibodies (1µg/µL, I.P.) and then every 4 days thereafter. The T cell depleted mice were treated with Anti-CD4 and Anti-CD8a antibodies (1µg/µL, I.P., every 4 days), Anti-CD4 + Anti-CD8a + RMC-7977 was treated with Anti-CD4 and Anti-CD8a antibodies (1µg/µL, I.P., every 4 days) and RMC-7977 (25 mg/kg, P.O., q.d.); and RMC-7977 group was treated with only RMC-7977 (25 mg/kg, P.O., q.d.) for 7 weeks. Plots correspond to each individual mouse. Dotted lines indicate when treatment started and stopped.

Article Snippet: For CD4 + and CD8 + T-cell depletion, specific antibodies (anti-CD4, clone YTS191; cat. #BE0003–1; BioXCell, RRID:AB_1107636 and anti-CD8a, clone YTS169.4, cat. #BE0117, BioXCell, RRID:AB_10950145) were used.

Techniques: Control, Injection

Journal: Cancer immunology research

Article Title: RAS(ON) multi-selective inhibition drives antitumor immunity in preclinical models of NRAS -mutant melanoma

doi: 10.1158/2326-6066.CIR-25-0744

Figure Lengend Snippet: (A-B) The effects of IgG control, anti-PD-1, RMC-7977 or anti-PD-1+RMC-7977 on the growth of OSUMMER.13 tumors. Treatment was initiated when tumors reached around 100mm 3 . The IgG group was treated with IgG control (2µg/µL, I.P., every 5 days: n=5), the vehicle group was treated with vehicle (P.O., q.d.: n=5), the vehicle + IgG group was treated with IgG control (2µg/µL, I.P., every 5 days: n=5) and vehicle (P.O., q.d.: n=5), total of n=15M for controls, the anti-PD-1 group was treated with Anti-PD-1 (2µg/µL, I.P., every 5 days: n=7), the RMC-7977 group was treated with RMC-7977 (25 mg/kg, P.O., q.d.: n=7), and the RMC-7977 + anti-PD-1 group (n=7) was treated with a combination of RMC-7977 and Anti-PD1 as indicated for 7 weeks. Plots correspond to each individual mouse. (C) Immunohistochemistry and quantification of pERK, Ki67, Melan-A, CD8, CD69, PD-1 and MHC-I of control (vehicle), anti-PD-1, RMC-7977 and RMC-7977 + anti-PD-1 group, n=3/group. H-score was used to access pERK, Ki67 and MHC-I expressions and the percentage of positive cells for melan-A and PD1, according to the best fit suggested by the software. Scale bar = 200 μm (D) Flow cytometry analysis of the T cell panel (number of infiltrated CD4 + and CD8 + T cells, activated CD4 + /CD69 + and CD8 + /CD69 + T cells, and memory CD44 + /CD62L − /CD4 + and CD44 + /CD62L − /CD8 + T cells) of vehicle, anti-PD1, RMC-7977 and the RMC-7977 + anti-PD-1 groups. The graphs are represented as average ± SEM. One-way ANOVA was performed followed by Tukey’s multiple comparisons test: *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. ns: non-significant. Dotted lines indicate when treatment started, stopped and when rechallenge was carried out.

Article Snippet: For CD4 + and CD8 + T-cell depletion, specific antibodies (anti-CD4, clone YTS191; cat. #BE0003–1; BioXCell, RRID:AB_1107636 and anti-CD8a, clone YTS169.4, cat. #BE0117, BioXCell, RRID:AB_10950145) were used.

Techniques: Control, Immunohistochemistry, Software, Flow Cytometry